Selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist with sustained signaling and absence of receptor desensitization or lymphocyte sequestration
A selective S1P1 receptor agonist developed by Trevena as a non-opioid treatment for diabetic neuropathic pain, distinguished from fingolimod-class functional antagonists by sustained receptor activation without S1P1R desensitization, protein downregulation, or peripheral lymphocyte depletion, and with additional preclinical evidence for anti-seizure activity.
Abstract
TRV045 (CAS 2256030-24-5) is a novel, orally bioavailable, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist under clinical development by Trevena, Inc. as a potential non-opioid treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy and, through a collaboration with the National Institutes of Health, as a potential treatment for epilepsy. The compound is distinguished from the approved S1P receptor modulator class (fingolimod, siponimod, ozanimod, ponesimod) by a pharmacological mechanism that produces sustained S1P1R agonism without the receptor internalization, functional desensitization, or S1P1R protein downregulation that characterizes fingolimod and related agents. The practical consequence of this mechanistic differentiation is the absence of peripheral lymphocyte sequestration (lymphopenia), the absence of first-dose bradycardia and atrioventricular conduction delay, and the absence of the immunosuppressive liability that defines the approved S1P modulator class and limits its application outside multiple sclerosis. Effects were sustained over 14 days of repeated dosing without evidence of tolerance, receptor desensitization, or S1P1R protein reduction in spinal cord tissue. In contrast, fingolimod in the same CIPN model produced approximately 70 percent reduction in S1P1R functional activity and 30 percent protein reduction. In human Phase 1 clinical studies, TRV045 has been evaluated in three completed trials comprising a first-in-human single and multiple ascending dose study in 89 healthy volunteers, a target engagement proof-of-concept study using the capsaicin-induced pain (PainCart) model in 25 healthy subjects, and a transcranial magnetic stimulation (TMS) and electroencephalography (EEG) proof-of-concept study in 25 healthy male subjects. Across all three completed Phase 1 studies, TRV045 demonstrated a favorable tolerability profile with no serious adverse events, no drug-related discontinuations, no clinically significant lymphopenia, no bradycardia, no blood pressure changes, and no prolongation of QTcF or PR intervals. The most common adverse events were mild headache, somnolence, dizziness, and fatigue. Trevena is advancing an optimized oral formulation through clinical pharmacokinetic evaluation in preparation for Phase 2 development. TRV045 is an investigational compound not approved by the United States Food and Drug Administration. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.